ENDOCRINE TUMORS: Edited by Christiane JungelsCirculating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinomaGiovanella, Lucaa,bAuthor Information aClinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Ente Ospedaliero Cantonale, Bellinzona bClinic for Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland Correspondence to Luca Giovanella, MD, PhD, Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Ente Ospedaliero Cantonale, Ospedale San Giovanni, Via Ospedale 12, 6500 Bellinzona, Switzerland. Tel: +0041 91 811 86 72; fax: +0041 91 811 82 50; e-mail: firstname.lastname@example.org Current Opinion in Oncology: January 2020 - Volume 32 - Issue 1 - p 7–12 doi: 10.1097/CCO.0000000000000588 Buy Metrics Abstract Purpose of review To discuss advances and challenges in thyroglobulin and Tg-antibody (TgAb) measurement and their impact on clinical management of differentiated thyroid carcinoma (DTC). Recent findings Basal high-sensitive Tg (hsTg) measurement avoids the need for stimulation and greatly simplifies DTC patients’ management. In addition, patients with undetectable hsTg after thyroid ablation are at a very low risk of recurrence and can be safely managed by periodic hsTg measurement alone. When TgAb is present, its trend over time serves as primary (surrogate) tumor marker. However, an undetectable hsTg measurement appears to indicate a complete remission of DTC even in the presence of TgAb. Finally, reliable reference values are not yet available for low-risk DTC who are treated with less than total thyroid ablation, and caution is needed before well-designed studies addressing these issues have been published. Summary The use of hsTg assays has changed paradigms for DTC monitoring even in the presence of TgAb, and greatly reduced patients’ discomfort and overall case-management costs. Reliable Tg interpretation criteria are urgently needed for patients treated with less than total thyroid ablation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.